1001 related articles for article (PubMed ID: 30742119)
1. Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma.
Zhao J; Chen AX; Gartrell RD; Silverman AM; Aparicio L; Chu T; Bordbar D; Shan D; Samanamud J; Mahajan A; Filip I; Orenbuch R; Goetz M; Yamaguchi JT; Cloney M; Horbinski C; Lukas RV; Raizer J; Rae AI; Yuan J; Canoll P; Bruce JN; Saenger YM; Sims P; Iwamoto FM; Sonabend AM; Rabadan R
Nat Med; 2019 Mar; 25(3):462-469. PubMed ID: 30742119
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.
Cloughesy TF; Mochizuki AY; Orpilla JR; Hugo W; Lee AH; Davidson TB; Wang AC; Ellingson BM; Rytlewski JA; Sanders CM; Kawaguchi ES; Du L; Li G; Yong WH; Gaffey SC; Cohen AL; Mellinghoff IK; Lee EQ; Reardon DA; O'Brien BJ; Butowski NA; Nghiemphu PL; Clarke JL; Arrillaga-Romany IC; Colman H; Kaley TJ; de Groot JF; Liau LM; Wen PY; Prins RM
Nat Med; 2019 Mar; 25(3):477-486. PubMed ID: 30742122
[TBL] [Abstract][Full Text] [Related]
3. Resolution of tissue signatures of therapy response in patients with recurrent GBM treated with neoadjuvant anti-PD1.
Lu Y; Ng AHC; Chow FE; Everson RG; Helmink BA; Tetzlaff MT; Thakur R; Wargo JA; Cloughesy TF; Prins RM; Heath JR
Nat Commun; 2021 Jun; 12(1):4031. PubMed ID: 34188042
[TBL] [Abstract][Full Text] [Related]
4. The N
Zhao R; Li B; Zhang S; He Z; Pan Z; Guo Q; Qiu W; Qi Y; Zhao S; Wang S; Chen Z; Zhang P; Guo X; Xue H; Li G
Front Immunol; 2021; 12():653711. PubMed ID: 34354698
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma.
Schalper KA; Rodriguez-Ruiz ME; Diez-Valle R; López-Janeiro A; Porciuncula A; Idoate MA; Inogés S; de Andrea C; López-Diaz de Cerio A; Tejada S; Berraondo P; Villarroel-Espindola F; Choi J; Gúrpide A; Giraldez M; Goicoechea I; Gallego Perez-Larraya J; Sanmamed MF; Perez-Gracia JL; Melero I
Nat Med; 2019 Mar; 25(3):470-476. PubMed ID: 30742120
[TBL] [Abstract][Full Text] [Related]
6. PTEN Mutations Trigger Resistance to Immunotherapy.
Cheng F; Eng C
Trends Mol Med; 2019 Jun; 25(6):461-463. PubMed ID: 30928438
[TBL] [Abstract][Full Text] [Related]
7. Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors.
Kim R; Keam B; Kim S; Kim M; Kim SH; Kim JW; Kim YJ; Kim TM; Jeon YK; Kim DW; Chung DH; Lee JS; Heo DS
BMC Cancer; 2019 Jan; 19(1):19. PubMed ID: 30616523
[TBL] [Abstract][Full Text] [Related]
8. Tumoral and immune heterogeneity in an anti-PD-1-responsive glioblastoma: a case study.
Restrepo P; Yong R; Laface I; Tsankova N; Nael K; Akturk G; Sebra R; Gnjatic S; Hormigo A; Losic B
Cold Spring Harb Mol Case Stud; 2020 Apr; 6(2):. PubMed ID: 31907277
[TBL] [Abstract][Full Text] [Related]
9. Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.
Reardon DA; Brandes AA; Omuro A; Mulholland P; Lim M; Wick A; Baehring J; Ahluwalia MS; Roth P; Bähr O; Phuphanich S; Sepulveda JM; De Souza P; Sahebjam S; Carleton M; Tatsuoka K; Taitt C; Zwirtes R; Sampson J; Weller M
JAMA Oncol; 2020 Jul; 6(7):1003-1010. PubMed ID: 32437507
[TBL] [Abstract][Full Text] [Related]
10. Long-term control and partial remission after initial pseudoprogression of glioblastoma by anti-PD-1 treatment with nivolumab.
Roth P; Valavanis A; Weller M
Neuro Oncol; 2017 Mar; 19(3):454-456. PubMed ID: 28039369
[No Abstract] [Full Text] [Related]
11. Machine learning revealed stemness features and a novel stemness-based classification with appealing implications in discriminating the prognosis, immunotherapy and temozolomide responses of 906 glioblastoma patients.
Wang Z; Wang Y; Yang T; Xing H; Wang Y; Gao L; Guo X; Xing B; Wang Y; Ma W
Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33839757
[TBL] [Abstract][Full Text] [Related]
12. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
Ng TL; Liu Y; Dimou A; Patil T; Aisner DL; Dong Z; Jiang T; Su C; Wu C; Ren S; Zhou C; Camidge DR
Cancer; 2019 Apr; 125(7):1038-1049. PubMed ID: 30548240
[TBL] [Abstract][Full Text] [Related]
13. Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinoma.
Liu S; Knochelmann HM; Lomeli SH; Hong A; Richardson M; Yang Z; Lim RJ; Wang Y; Dumitras C; Krysan K; Timmers C; Romeo MJ; Krieg C; O'Quinn EC; Horton JD; Dubinett SM; Paulos CM; Neskey DM; Lo RS
Cell Rep Med; 2021 Oct; 2(10):100411. PubMed ID: 34755131
[TBL] [Abstract][Full Text] [Related]
14. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
[TBL] [Abstract][Full Text] [Related]
15. Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF.
Di Tacchio M; Macas J; Weissenberger J; Sommer K; Bähr O; Steinbach JP; Senft C; Seifert V; Glas M; Herrlinger U; Krex D; Meinhardt M; Weyerbrock A; Timmer M; Goldbrunner R; Deckert M; Scheel AH; Büttner R; Grauer OM; Schittenhelm J; Tabatabai G; Harter PN; Günther S; Devraj K; Plate KH; Reiss Y
Cancer Immunol Res; 2019 Dec; 7(12):1910-1927. PubMed ID: 31597643
[TBL] [Abstract][Full Text] [Related]
16. Genomic and transcriptomic correlates of immunotherapy response within the tumor microenvironment of leptomeningeal metastases.
Prakadan SM; Alvarez-Breckenridge CA; Markson SC; Kim AE; Klein RH; Nayyar N; Navia AW; Kuter BM; Kolb KE; Bihun I; Mora JL; Bertalan MS; Shaw B; White M; Kaplan A; Stocking JH; Wadsworth MH; Lee EQ; Chukwueke U; Wang N; Subramanian M; Rotem D; Cahill DP; Adalsteinsson VA; Miller JW; Sullivan RJ; Carter SL; Brastianos PK; Shalek AK
Nat Commun; 2021 Oct; 12(1):5955. PubMed ID: 34642316
[TBL] [Abstract][Full Text] [Related]
17. Durable Response to Nivolumab in a Pediatric Patient with Refractory Glioblastoma and Constitutional Biallelic Mismatch Repair Deficiency.
AlHarbi M; Ali Mobark N; AlMubarak L; Aljelaify R; AlSaeed M; Almutairi A; Alqubaishi F; Hussain ME; Balbaid AAO; Said Marie A; AlSubaie L; AlShieban S; alTassan N; Ramkissoon SH; Abedalthagafi M
Oncologist; 2018 Dec; 23(12):1401-1406. PubMed ID: 30104292
[TBL] [Abstract][Full Text] [Related]
18. Combination anti-CXCR4 and anti-PD-1 immunotherapy provides survival benefit in glioblastoma through immune cell modulation of tumor microenvironment.
Wu A; Maxwell R; Xia Y; Cardarelli P; Oyasu M; Belcaid Z; Kim E; Hung A; Luksik AS; Garzon-Muvdi T; Jackson CM; Mathios D; Theodros D; Cogswell J; Brem H; Pardoll DM; Lim M
J Neurooncol; 2019 Jun; 143(2):241-249. PubMed ID: 31025274
[TBL] [Abstract][Full Text] [Related]
19. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
Toi Y; Sugawara S; Sugisaka J; Ono H; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
JAMA Oncol; 2019 Mar; 5(3):376-383. PubMed ID: 30589930
[TBL] [Abstract][Full Text] [Related]
20. Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations.
Ascierto PA; Capone M; Grimaldi AM; Mallardo D; Simeone E; Madonna G; Roder H; Meyer K; Asmellash S; Oliveira C; Roder J; Grigorieva J
J Immunother Cancer; 2019 Mar; 7(1):91. PubMed ID: 30925943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
